Ingrid Choong, PhD

Head of Corporate Development

Dr. Choong is an industry veteran with more than 20 years of operational experience in private and public, emerging-stage biotech companies with an established track record of building and leading high performing clinical and regulatory development teams, business development and pipeline development, including product assessment, license negotiation, strategic partnerships, and alliance management.

Most recently, Dr. Choong was Chief Business Officer at LIB Therapeutics which completed Phase 3 global registration-enabling trials for its lead cardiovascular disease program, submitted for regulatory approval, and announced a $325 million strategic development and commercial collaboration in China. Previously, Dr. Choong was founding member and SVP of Clinical and Corporate Development at Eiger BioPharmaceuticals which obtained FDA and EMA approval and launched the first therapy to extend survival in Hutchinson-Gilford progeria syndrome, an ultra-rare and fatal pediatric disease. Dr. Choong began her emerging-stage biotech career as a scientist at Sunesis Pharmaceuticals in discovery research.

Dr. Choong earned a BS in Chemistry from the California Institute of Technology and a PhD from University of California at Berkeley.